153 related articles for article (PubMed ID: 24846709)
21. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
22. Challenges of developing palatable oral paediatric formulations.
Cram A; Breitkreutz J; Desset-Brèthes S; Nunn T; Tuleu C;
Int J Pharm; 2009 Jan; 365(1-2):1-3. PubMed ID: 18848611
[No Abstract] [Full Text] [Related]
23. Experimental models for predicting drug absorption and metabolism.
Alqahtani S; Mohamed LA; Kaddoumi A
Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1241-54. PubMed ID: 23687990
[TBL] [Abstract][Full Text] [Related]
24. Why we need proper PBPK models to examine intestine and liver oral drug absorption.
Chow EC; Pang KS
Curr Drug Metab; 2013 Jan; 14(1):57-79. PubMed ID: 22935069
[TBL] [Abstract][Full Text] [Related]
25. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
26. Developmental pharmacokinetics.
Anderson GD
Semin Pediatr Neurol; 2010 Dec; 17(4):208-13. PubMed ID: 21183126
[TBL] [Abstract][Full Text] [Related]
27. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
28. Strategies to improve oral drug bioavailability.
Gomez-Orellana I
Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
[TBL] [Abstract][Full Text] [Related]
29. Pediatric pharmacokinetics: human development and drug disposition.
Funk RS; Brown JT; Abdel-Rahman SM
Pediatr Clin North Am; 2012 Oct; 59(5):1001-16. PubMed ID: 23036241
[TBL] [Abstract][Full Text] [Related]
30. Oral biopharmaceutics-current status and identified gaps of understanding.
Lennernäs H; Abrahamsson P; Langguth B
Eur J Pharm Sci; 2014 Jun; 57():98. PubMed ID: 24508580
[No Abstract] [Full Text] [Related]
31. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
32. Drug doses for children. A rational approach to an old problem.
Habersang R; Kauffman RE
J Kans Med Soc; 1974 Mar; 75(3):98-103. PubMed ID: 4593019
[No Abstract] [Full Text] [Related]
33. A timely reassessment of early prediction in the bioavailability of orally administered drugs.
Larsen T; Link A
Angew Chem Int Ed Engl; 2005 Jul; 44(29):4432-4. PubMed ID: 15984039
[No Abstract] [Full Text] [Related]
34. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption.
del Amo EM; Heikkinen AT; Mönkkönen J
Eur J Pharm Sci; 2009 Feb; 36(2-3):200-11. PubMed ID: 19063964
[TBL] [Abstract][Full Text] [Related]
35. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
Porter CJ; Trevaskis NL; Charman WN
Nat Rev Drug Discov; 2007 Mar; 6(3):231-48. PubMed ID: 17330072
[TBL] [Abstract][Full Text] [Related]
36. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
Novak E; Allen PJ
Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
[TBL] [Abstract][Full Text] [Related]
37. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
38. Dosing considerations in the pediatric patient.
Skaer TL
Clin Ther; 1991; 13(5):526-44; discussion 525. PubMed ID: 1799910
[TBL] [Abstract][Full Text] [Related]
39. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
Otsuka K; Shono Y; Dressman J
J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
[TBL] [Abstract][Full Text] [Related]
40. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
